Post-earnings recap
Reported
Wed, Feb 25, 2026
EPS actual
$-3.58
EPS est.
$-1.03
EPS surprise
-248.59%
1-day move
+0.69%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Sarepta Therapeutics reported a significant loss per share, which was expected given the lack of revenue data. Despite the disappointing EPS, the stock saw a modest increase of 0.69%, possibly due to investors focusing on long-term strategies rather than short-term losses. The absence of guidance may leave some investors cautious about the company's future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-3.58 | N/A | -248.59% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about the current financial performance but remains committed to their long-term goals. They did not provide specific guidance for the future.
Management acknowledged the challenges faced this quarter.
They emphasized a focus on long-term strategy despite current setbacks.